Page 48 - 68_02
P. 48
68 (2), FUNDAMENTOS DE LAS INTERACCIONES FARMACOCINÉTICAS
(56) TOTTER, T.N., ROBWOTHAM, D.J., WINDRAM, I., MUSHAMBI, M.C. (1991): Effect
of sublingual buprenorphine on gastric emptying of a liquid meal. Br. J. Anaesth.
67:748-750.
(57) NIMMO, W.S., HEADING, R.C., WILSON, J. (1975): Inhibition of gastric emptying
and drug absorption by narcotic analgesics. Br. J.. Clin. Pharmacol. 2:509-513.
(58) NAHUM, M.P., BEN ARUSH, M.W., ROBINSON, E. (1990): Reduced plasma car-
bamazepine level during chemotherapy in a child with malignant lymphoma. Acta
Paed. Scand. 79:873-875.
(59) NEEF, C., DE VOOGD-VAN DER STRAATEN, I. (1988): An interaction between cy-
tostatic and anticonvulsivant drugs. Clin. Pharmacol. Ther. 43:372-375.
(60) GIBALDI, M., PERRIER, D. (1982). Pharmacokinetics. 2nd edition. Marcel Dekker,
Inc. New York.
(61) LA DU, B.N., MANDEL, H.G., WAY, E.L. (1981). Fundamentals of drug metabo-
lism and drug disposition. The Williams and Wilkins Co. Baltimore.
(62) OIE, S., LEVY, G. (1979): Effect of sulfixoxazole on pharmacokinetics o free and
plasma protein-bound bilirrubin in experimental unconjugated hyperbilirrubine-
miae. J. Pharm. Sci. 68(1):6-8.
(63) SZITA, M., GACHÁLYI, B., TORNYOSSY, M., KÁLDOR, A. (1990): Interaction of
phenylbutazone and tolbutamide in man. Int. J. Clin. Pharmacol. Ther. Toxicol.
18:378-380.
(64) SPEDERS, S. (1993): Mofebutazon-Prufung einer moglichen interaktion mit
glibenclamid. Fortschritte der Medizin. 111:366-368.
(65) LEWIS, R.J., TRAGER, W.F., CHAN, K.K., BRECKENRIDGE, A., ORME, M., ROW-
LAND, M., SCHARY, W. (1974): Warfarin stereochemical aspects of its metabolism
and the interaction with phenylbutazone. J. Clin. Invest. 53:1607.
(66) O´REILLY, R.A. (1973): The binding of sodium warfarin to plasma albumin and
its displacement by phenylbutazone. Ann. NY. Acad. Sci. 226:293.
(67) UDALL, J.A. (1974): Warfarin-chloral hydrate interaction. Pharmacological activ-
ity and significance. Ann. Int. Med. 81:341.
(68) BRIDGMAN, J.F., ROSEN, S.M., THORP, J.M. (1972): Complications during clofi-
brate treatment of nephritic syndrome hyperlipoproteinaemia. Lancet. ii: 506.
(69) MAY, T.W., RAMBECK, B., NORTHBAUM, N. (1991): Nomogram for the prediction
of unbound phenytoin concentrations in patients on a combined treatment of
phenytoin and valproic acid. Eur. Neurol. 31:57-60.
(70) SACKELLARES, J.C., SATO, S., DREIFUSS, F.E., PENRY, J.K. (1981): Reduction of
steady-state valproate levels by other antiepileptic drugs. Epilepsia 22:437-441.
(71) WALLACE, S.M., VERBEECK, R.K. (1987): Plasma protein binding of drugs in the
elderly. Clin. Pharmacokin. 12:41-72.
171
